Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Current Assets (2016 - 2025)

Arcadia Biosciences' Current Assets history spans 12 years, with the latest figure at $6.4 million for Q4 2025.

  • For Q4 2025, Current Assets fell 31.23% year-over-year to $6.4 million; the TTM value through Dec 2025 reached $6.4 million, down 31.23%, while the annual FY2025 figure was $6.4 million, 31.23% down from the prior year.
  • Current Assets reached $6.4 million in Q4 2025 per RKDA's latest filing, down from $8.4 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $56.6 million in Q1 2021 to a low of $6.4 million in Q4 2025.
  • Average Current Assets over 5 years is $23.2 million, with a median of $21.7 million recorded in 2023.
  • Peak YoY movement for Current Assets: surged 138.29% in 2021, then plummeted 57.21% in 2024.
  • A 5-year view of Current Assets shows it stood at $35.4 million in 2021, then dropped by 28.23% to $25.4 million in 2022, then plummeted by 41.05% to $15.0 million in 2023, then plummeted by 38.27% to $9.2 million in 2024, then plummeted by 31.23% to $6.4 million in 2025.
  • Per Business Quant, the three most recent readings for RKDA's Current Assets are $6.4 million (Q4 2025), $8.4 million (Q3 2025), and $7.6 million (Q2 2025).